# Cresilon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cresilon

- Industry: Biotechnology
- Headquarters: Brooklyn, US
- Website: www.cresilon.com
- Total disclosed funding: $25M
- Latest round: Series A (Dec 17, 2021)
- Investors on record: 3

## About

Cresilon, Inc., based in the US, specializes in innovative hemostatic solutions for veterinary and human medical applications, focusing on rapid bleeding control and product development.Cresilon, Inc. is dedicated to developing hemostatic technology for medical applications. Founded in 2010 and headquartered in Brooklyn, US, the company has engaged in 7 deals, with the most recent funding being a Series A round led by Paulson Investment Company on December 17, 2021, raising USD 25.00 mn. The co-founders, Isaac Miller and Joe Landolina, have contributed to the company's mission of advancing medical technology solutions.Cresilon, Inc. specializes in the development and commercialization of hemostatic technology for both veterinary and human medical applications. The company’s flagship product, VETIGEL®, is a single-use, prescription hemostatic gel designed specifically for veterinary use, effectively controlling bleeding within seconds upon contact with a wound. This plant-based gel utilizes proprietary polymers that form a mechanical seal, eliminating the need for manual pressure, thereby supporting the natural clotting process in animals. Cresilon’s product offerings extend beyond VETIGEL®, focusing on trauma and surgical care solutions for both veterinary and human markets, with ongoing research and development aimed at expanding its product line. The company’s client base includes veterinary clinics, animal hospitals, and potentially human medical facilities; its products are marketed internationally, reaching various geographical markets including North America, Europe, and select regions in Asia.Cresilon generates revenue primarily through the sale of its medical device products, specifically focusing on veterinary applications. Transactions typically occur through direct sales to veterinary clinics and hospitals, establishing partnerships that enable wider distribution of VETIGEL® and its planned future products. The pricing structure for products like VETIGEL® is set as a single transaction per unit, aligning with the needs of veterinary practitioners who require immediate, reliable solutions for controlling bleeding in animals. The revenue model is designed to facilitate direct purchasing from Cresilon, with potential future avenues for subscription or partnership agreements as the product line expands. Overall, Cresilon's business model emphasizes direct-to-consumer sales within the veterinary sector while strategically positioning itself for potential entry into the human medical market in the future.In December 2021, Cresilon, Inc. secured USD 25.00 mn in Series A funding, led by Paulson Investment Company. The company plans to utilize this funding to introduce its product to the human health sector while expanding its global business reach. Cresilon aims to launch new products designed for the human medical market and is targeting expansion into additional geographical regions including Europe and Asia by 2023.

## Funding rounds

- Series A, Dec 17, 2021, $25M — Paulson Investment Company
- Series A, May 22, 2015 — Innovating Capital
- Seed, Jun 1, 2013 — Dorm Room Fund

## Investors

- Dorm Room Fund (https://capitalatlas.ai/funds/dorm-room-fund) — Seed
- Innovating Capital (https://capitalatlas.ai/funds/innovating-capital) — Series A
- Paulson Investment Company (https://capitalatlas.ai/funds/paulson-investment-company) — Series A